SCYX

SCYNEXIS, Inc.

2.73 USD
-0.04 (-1.44%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

SCYNEXIS, Inc. stock is up 93.62% since 30 days ago. The next earnings date is Aug 12, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 10 May’s closed higher than April.

About SCYNEXIS, Inc.

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited and R-Pharm, CJSC.